143 related articles for article (PubMed ID: 30882666)
1. ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.
Qiu Y; Li B; Zhang Y; Guo X; Xiang C; Wang C; Lu Y; Ren S; Zhao J
Medicine (Baltimore); 2019 Mar; 98(11):e14826. PubMed ID: 30882666
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
Guisier F; Piton N; Bellefleur M; Delberghe N; Avenel G; Angot E; Vittecoq O; Ould-Slimane M; Morisse-Pradier H; Salaun M; Thiberville L
BMC Cancer; 2020 Jan; 20(1):14. PubMed ID: 31906956
[TBL] [Abstract][Full Text] [Related]
3. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
4. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
5. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract][Full Text] [Related]
6. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
Guo J; Shi J; Yao M; Jin Y; Liu D; Liu W; Wang K; Jiang D
Medicine (Baltimore); 2020 Nov; 99(45):e22631. PubMed ID: 33157918
[TBL] [Abstract][Full Text] [Related]
7. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety.
Wang M; Wang G; Ma H; Shan B
Curr Cancer Drug Targets; 2019; 19(1):41-49. PubMed ID: 28669346
[TBL] [Abstract][Full Text] [Related]
9. Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
Mattar MS; Chang J; Benayed R; Halpenny D; Powers A; Kleiner DE; Drilon A; Kris MG
Clin Lung Cancer; 2020 Jan; 21(1):e25-e29. PubMed ID: 31690489
[No Abstract] [Full Text] [Related]
10. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
11. Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.
Jing X; Li F; Meng X; Liu Z; Yu J; Liu B
Cancer Biol Ther; 2017 May; 18(5):279-284. PubMed ID: 28362192
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
13. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
14. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
15. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
Zheng J; Zhu Y; Sun K; Shen Q; Wang Y; Cao H; Lizaso A; Yu B; Lin J; Chen S; Zhou J; Zhou J
Lung Cancer; 2020 Aug; 146():209-216. PubMed ID: 32563740
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
Zhang B; Zhang Y; Xu J; Zhang X; Chu T; Wang S; Qian J; Qiao R; Lu J; Zhang L; Han B
Target Oncol; 2018 Oct; 13(5):631-639. PubMed ID: 30218431
[TBL] [Abstract][Full Text] [Related]
17. A novel
Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
[TBL] [Abstract][Full Text] [Related]
18. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
19. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability.
Kilickap S; Onder S; Dizdar O; Erman M; Uner A
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1195-1196. PubMed ID: 30863883
[TBL] [Abstract][Full Text] [Related]
20. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
